Radiolabelling

Designing and developing novel radiopharmaceuticals requires skill and knowledge about radiochemical processes. We have experience in radiolabelling radiopharmaceuticals with several radionuclides, including 11-C, 18-F, Ga-68 (for PET), I-123 (for SPECT), Lu-177 (for beta emitter therapy) and both At-211 and Pb-212 (for alpha emitter therapy).

Having hands-on expertise and qualification for carrying out radiolabelling, we can perform projects on-site at the customer. In addition, we are currently seeking to gain access to laboratory facilities for performing radiochemistry projects.